Ruling in Risperdal case does not affect Taiwan users: official
Taipei, April 12 (CNA) Taiwan's Department of Health said Thursday that local patients using the drug Risperdal would not be affected by a ruling in the United States that fined Johnson & Johnson and a subsidiary, the drug's manufacturer, for improperly marketing the drug and downplaying its potential health risks.
Access to articles dating back more than six months is not available free of charge. You can gain access by becoming a paid Focus Taiwan member.
※This website's content, including but not limited to text, images and video, cannot be reproduced, retransmitted or publicly broadcast without the authorization of CNA.